Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Diabetes & Metabolic Disorders
Published in: Journal of Diabetes & Metabolic Disorders 2/2020

01-12-2020 | Obesity | Review article

A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity

Authors: Mandana Hasanzad, Negar Sarhangi, Shekoufeh Nikfar, Seyed Naser Ostad, Hamid Reza Aghaei Meybodi

Published in: Journal of Diabetes & Metabolic Disorders | Issue 2/2020

Login to get access

Abstract

Liraglutide is a long-acting human glucagon-like peptide-1 (GLP-1) analogue and an effective treatment for patients with metabolic diseases including type 2 diabetes mellitus (T2DM) and obesity. This review focuses on the mechanism of action of liraglutide as a well-known glucagon-like peptide-1 receptor agonist (GLP-1 RA) in patients with T2DM and obesity. The lower and the higher doses of GLP-1 RAs are used for glycaemic control in T2DM and in obesity respectively. GLP-1 RAs such as liraglutide enhance insulin secretion and inhibit glucagon release via the stimulation of glucagon-like peptide-1 receptors (GLP-1Rs). Liraglutide decreases hemoglobin A1c (HbA1c) in type 2 diabetes (T2D) patients when prescribes as monotherapy or in combination with one or more antidiabetic drugs. Usually, it is well tolerated with minor hypoglycemia in combination therapy. Liraglutide reduces cardiovascular events and related risk factors including improvement of lipid profile and control of blood pressure. Accordingly, it can be cost-effective and may be a budget neutral medication option by considering its protective effect on the cardiovascular system in long-term use in the health care plan. In the near future, by pharmacogenomics approach, prediction of the highest patient’s response with the lowest adverse drug reactions and also rationality of drug development will be possible. Liraglutide can be used as a desirable medicine for glycemic control and obesity. It shows extensive evidence based benefits in diabetes complications. In this narrative review, we have summarized and evaluated studies related to the role of liraglutide in clinical practice.
Literature
1.
Ginsberg HN, MacCallum PR. The obesity, metabolic syndrome, and type 2 diabetes mellitus pandemic: part I. increased cardiovascular disease risk and the importance of atherogenic dyslipidemia in persons with the metabolic syndrome and type 2 diabetes mellitus. J Cardiometab Syndr. 2009;4(2):113–9.PubMedPubMedCentralCrossRef
2.
3.
Care D. Standards of Medical Care in Diabetesd 2019. Diabetes Care. 2019;42:S81.CrossRef
4.
Peykari N, Hashemi H, Dinarvand R, Haji-Aghajani M, Malekzadeh R, Sadrolsadat A, et al. National action plan for non-communicable diseases prevention and control in Iran; a response to emerging epidemic. J Diabetes Metab Disord. 2017;16(1):3.PubMedPubMedCentralCrossRef
5.
DeFronzo RA. From the triumvirate to the „ominous octet”: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009; 58(4): 773–795.
6.
Gadde KM, Martin CK, Berthoud HR, Heymsfield SB. Obesity: pathophysiology and management. Diabetes Obes Metab. 2018;71(1):69–84.
7.
The American Diabetes Association (ADA). Diagnosis and classification of diabetes mellitus. Diabetes care. 2010;33(Supplement 1):S62-S9.
8.
Boutayeb A, Boutayeb S, Boutayeb W. Multi-morbidity of non communicable diseases and equity in WHO eastern Mediterranean countries. Int J Equity Health. 2013;12(1):60.PubMedPubMedCentralCrossRef
9.
Flegal KM, Kit BK, Orpana H, Graubard BI. Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA. 2013;309(1):71–82.PubMedPubMedCentralCrossRef
10.
Nauck MA, Meier JJ. Incretin hormones: their role in health and disease. Diabetes Obes Metab. 2018;20(Suppl 1):5–21.PubMedCrossRef
11.
12.
Romera I, Cebrian-Cuenca A, Alvarez-Guisasola F, Gomez-Peralta F, Reviriego J. A review of practical issues on the use of glucagon-like Peptide-1 receptor agonists for the Management of Type 2 diabetes. Diabetes Ther. 2018;10(1):5–19.PubMedPubMedCentralCrossRef
13.
Phillips LK, Prins JB. Update on incretin hormones. Ann N Y Acad Sci. 2011;1243(1).
14.
Poon JL, Watson K, Del Olmo-Garcia MI. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. Pharmacotherapy. 2018;2018:4020492.
15.
Holst JJ. Incretin hormones and the satiation signal. Int J Obes. 2013;37(9):1161–8.CrossRef
16.
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Ørskov C, Ritzel R, et al. Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab. 1997;273(5):E981–E8.CrossRef
17.
Bahtiyar G, Pujals-Kury J, Sacerdote A. Cardiovascular effects of different GLP-1 receptor agonists in patients with type 2 diabetes. Curr Diab Rep. 2018;18(10):92.PubMedCrossRef
18.
Chaudhury A, Duvoor C, Dendi R, Sena V, Kraleti S, Chada A, et al. Clinical review of antidiabetic drugs: Implications for type 2 diabetes mellitus management. Front Endocrinol (Lausanne). 2017;8:6.
19.
Toft-Nielsen M-B, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717–23.PubMedCrossRef
20.
Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur J Intern Med. 2014;25(5):407–14.PubMedCrossRef
21.
Filippatos TD, Panagiotopoulou TV, Elisaf MS. Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud. 2014;11(3):202–30.PubMedCrossRef
22.
Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131–57.PubMedCrossRef
23.
Hui H, Farilla L, Merkel P, Perfetti R. The short half-life of glucagon-like peptide-1 in plasma does not reflect its long-lasting beneficial effects. Eur J Endocrinol. 2002;146(6):863–9.PubMedCrossRef
24.
Jackson SH, Martin TS, Jones JD, Seal D, Emanuel F. Liraglutide (victoza): the first once-daily incretin mimetic injection for type-2 diabetes. Pharmacol Ther. 2010;35(9):498.
25.
Sharma D, Verma S, Vaidya S, Kalia K, Tiwari V. Recent updates on GLP-1 agonists: current advancements & challenges. Biomed Pharmacother. 2018;108:952–62.PubMedCrossRef
26.
Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: a review of their efficacy and tolerability. Diabetes Care. 2011;34(Supplement 2):S279–S84.PubMedPubMedCentralCrossRef
27.
Sethi B, Viswanathan V, Kumar A, Chatterjee S, Chandalia H. Liraglutide in clinical practice: insights from LEAD programme. JAPI. 2010;58:18–22.
28.
Gough SC, Jain R, Woo VC. Insulin degludec/liraglutide (IDegLira) for the treatment of type 2 diabetes. Expert Rev Endocrinol Metab. 2016;11(1):7–19.PubMedCrossRef
29.
Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27(8):1879–84.PubMedCrossRef
30.
Buse JB, Committee LS. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J of Med. 2016;375(18):1798.
31.
Zinman B, Marso SP, Christiansen E, Calanna S, Rasmussen S, Buse JB. Hypoglycemia, Cardiovascular Outcomes, and Death: The LEADER Experience. Diabetes Care. 2018:dc172677.
32.
Mann JF, Ørsted DD, Brown-Frandsen K, Marso SP, Poulter NR, Rasmussen S, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J of Med. 2017;377(9):839–48.CrossRef
33.
Plutzky J, Garber A, Toft A, Poulter N, editors. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue, significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes. Diabetologia; 2009: SPRINGER 233 SPRING ST, NEW YORK, NY 10013 USA.
34.
Fonseca VA, DeVries JH, Henry RR, Donsmark M, Thomsen HF, Plutzky J. Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: insights from a patient-level pooled analysis of six randomized clinical trials. J Diabetes Complicat. 2014;28(3):399–405.CrossRef
35.
Buse JB, Bain SC, Mann JF, Nauck MA, Nissen SE, Pocock S, et al. Cardiovascular risk reduction with liraglutide: an exploratory mediation analysis of the LEADER trial. Diabetes Care. 2020;43:1546–52.PubMedPubMedCentralCrossRef
36.
Matyjaszek-Matuszek B, Szafraniec A, Porada D. Pharmacotherapy of obesity - state of the art. Endokrynol Pol. 2018;69(4).
37.
Farr OM, Sofopoulos M, Tsoukas MA, Dincer F, Thakkar B, Sahin-Efe A, et al. GLP-1 receptors exist in the parietal cortex, hypothalamus and medulla of human brains and the GLP-1 analogue liraglutide alters brain activity related to highly desirable food cues in individuals with diabetes: a crossover, randomised, placebo-controlled trial. Diabetologia. 2016;59(5):954–65.PubMedPubMedCentralCrossRef
38.
Saunders KH, Umashanker D, Igel LI, Kumar RB, Aronne LJ. Obesity pharmacotherapy. Med Clin North Am. 2018;102(1):135–48.PubMedCrossRef
39.
Pi-Sunyer X, Astrup A, Fujioka K, Greenway F, Halpern A, Krempf M, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J of Med. 2015;373(1):11–22.CrossRef
40.
Wadden TA, Hollander P, Klein S, Niswender K, Woo V, Hale P, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes. 2013;37(11):1443–51.CrossRef
41.
Davies MJ, Bergenstal R, Bode B, Kushner RF, Lewin A, Skjøth TV, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–99.PubMedCrossRef
42.
Blackman A, Foster G, Zammit G, Rosenberg R, Aronne L, Wadden T, et al. Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial. Int J Obes (Lond). 2016;40(8):1310.CrossRef
43.
Khera R, Pandey A, Chandar AK, Murad MH, Prokop LJ, Neeland IJ, et al. Effects of weight-loss medications on cardiometabolic risk profiles: a systematic review and network meta-analysis. Gastroenterology. 2018;154(5):1309–19 e7.PubMedCrossRef
44.
Garvey WT, Birkenfeld AL, Dicker D, Mingrone G, Pedersen SD, Satylganova A, et al. Efficacy and safety of Liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial. Diabetes Care. 2020;43(5):1085–93.PubMedPubMedCentralCrossRef
45.
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117–28.PubMedCrossRef
46.
Iepsen EW, Zhang J, Thomsen HS, Hansen EL, Hollensted M, Madsbad S, et al. Patients with obesity caused by Melanocortin-4 receptor mutations can be treated with a glucagon-like Peptide-1 receptor agonist. Cell Metab. 2018;28:23–32.e3.PubMedCrossRef
47.
Wang FF, Wu Y, Zhu YH, Ding T, Batterham R, Qu F, et al. Pharmacologic therapy to induce weight loss in women who have obesity/overweight with polycystic ovary syndrome: a systematic review and network meta-analysis. Obes Rev. 2018;19(10):1424–45.PubMedCrossRef
48.
Talmor A, Dunphy B. Female obesity and infertility. Best Pract Res Clin Obstet Gynaecol. 2015;29(4):498–506.PubMedCrossRef
49.
Yildiz BO. Polycystic ovary syndrome: is obesity a symptom? Womens Health (Lond). 2013;9(6):505–7.CrossRef
50.
Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;1(8):105.
51.
Han Y, Li Y, He B. GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis. Reprod BioMed Online. 2019;39(2):332–42.PubMedCrossRef
52.
Crews KR, Hicks JK, Pui CH, Relling MV, Evans WE. Pharmacogenomics and individualized medicine: translating science into practice. Clin Pharmacol Ther. 2012;92(4):467–75.PubMed
53.
54.
Tkáč I, Gotthardová I. Pharmacogenetic aspects of the treatment of type 2 diabetes with the incretin effect enhancers. Pharmacogenomics. 2016;17(7):795–804.PubMedCrossRef
55.
de Luis DA, Soto GD, Izaola O, Romero E. Evaluation of weight loss and metabolic changes in diabetic patients treated with liraglutide, effect of RS 6923761 gene variant of glucagon-like peptide 1 receptor. J Diabetes Complicat. 2015;29(4):595–8.CrossRef
56.
de Luis DA, Ovalle HF, Soto GD, Izaola O, de la Fuente B, Romero E. Role of genetic variation in the cannabinoid receptor gene (CNR1)(G1359A polymorphism) on weight loss and cardiovascular risk factors after liraglutide treatment in obese patients with diabetes mellitus type 2. J Investig Med. 2014;62(2):324–7.PubMedCrossRef
57.
58.
Hauner H. The mode of action of thiazolidinediones. Diabetes Metab Res Rev. 2002;18(Suppl 2):S10–5.PubMedCrossRef
59.
Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. Sulfonylureas and their use in clinical practice. Arch Med Sci. 2015;11(4):840–8.PubMedPubMedCentralCrossRef
60.
DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 2000;133(1):73–4.PubMedCrossRef
61.
Guardado-Mendoza R, Prioletta A, Jiménez-Ceja LM, Sosale A, Folli F. The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch Med Sci. 2013;9(5):936–43.PubMedPubMedCentralCrossRef
62.
Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–86.PubMedCrossRef
63.
64.
Metadata
Title
A narrative review of current trends in liraglutide: insights into the unmet needs in management of type 2 diabetes and obesity
Authors
Mandana Hasanzad
Negar Sarhangi
Shekoufeh Nikfar
Seyed Naser Ostad
Hamid Reza Aghaei Meybodi
Publication date
01-12-2020
Publisher
Springer International Publishing
Published in
Journal of Diabetes & Metabolic Disorders / Issue 2/2020
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1007/s40200-020-00619-9

Other articles of this Issue 2/2020

Journal of Diabetes & Metabolic Disorders 2/2020 Go to the issue

Study Protocol

CREATE (Community deRivEd AutomaTEd insulin delivery) trial. Randomised parallel arm open label clinical trial comparing automated insulin delivery using a mobile controller (AnyDANA-loop) with an open-source algorithm with sensor augmented pump therapy in type 1 diabetes

Research article

Glycemic control and associated factors among Iranian population with type 2 diabetes mellitus: a cross-sectional study

Research article

Assessing impaired fasting blood glucose criteria for high-risk dysglycaemic populations: an experience from a European population state

Commentary

A brief analysis and hypotheses about the risk of COVID-19 for people with type 1 and type 2 diabetes mellitus

Review article

Type 2 diabetes mellitus: pathogenesis and genetic diagnosis

Research article

The effect of collaborative care model training on diabetic foot ulcer patients’ quality of life: a semi-experimental study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits